<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651868</url>
  </required_header>
  <id_info>
    <org_study_id>H-20039104</org_study_id>
    <nct_id>NCT04651868</nct_id>
  </id_info>
  <brief_title>The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying</brief_title>
  <official_title>The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordisk Foundation Center for Basic Metabolic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blinded, placebo-controlled, cross-over study, which will&#xD;
      investigate the acute effects of the gut-derived hormone glucagon-like peptide 2 (GLP-2) on&#xD;
      cholecystokinin (CCK)-induced gallbladder emptying. Furthermore, the investigators will&#xD;
      investigate different hormonal responses and appetite during the study days.&#xD;
&#xD;
      The investigators hypothesize that GLP-2 will overrule the potent gallbladder relaxing effect&#xD;
      of CCK.&#xD;
&#xD;
      We will include 15 healthy male participants, and each of the participants will participate&#xD;
      in four study days. GLP-2 and CCK will be given intravenously, and will be&#xD;
      placebo-controlled. Gallbladder volume will be determined by frequent ultrasonography scans.&#xD;
      Appetite will be assessed by Visual Analog Scales through out the study day and an ad libitum&#xD;
      meal at the end of the study day. Blood samples will be drawn at regular intervals to asses&#xD;
      different hormonal responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      AIM OF THE STUDY The aim of the study is to investigate if exogenous GLP-2 can overrule&#xD;
      CCK-induced gallbladder contraction&#xD;
&#xD;
      STUDY DESIGN The study is a randomized, double-blinded, placebo-controlled, crossover study&#xD;
      enrolling 15 healthy participants. Each participant will undergo four separate study days in&#xD;
      randomized order. Each study day encompasses two intravenous (iv) infusions, one with CCK&#xD;
      (0.4 pmol × kg^-1 × min^-1) or placebo (saline), and one with GLP-2 (10 pmol × kg^-1 ×&#xD;
      min^-1) or placebo (saline): Day A, CCK + GLP-2; Day B, CCK + placebo; Day C, placebo +&#xD;
      GLP-2; Day D, placebo + placebo.&#xD;
&#xD;
      METHODS For each participant, the study consists of an information visit, a screening visit&#xD;
      and four experimental days within a time period of minimum 2 months, and with a minimum of&#xD;
      three days between each experimental day with procedures explained below.&#xD;
&#xD;
      RECRUITMENT OF PARTICIPANTS Relevant persons, who have previously participated in trials at&#xD;
      the investigators research facility and at that time accepted to be contacted again regarding&#xD;
      other research projects will be contacted by telephone or e-mail. Alternatively,&#xD;
      advertisements regarding the project will be published at www.forsoegsperson.dk, other&#xD;
      relevant internet / social media pages and/or local or national newspapers. Persons&#xD;
      responding positively will receive the written information. A couple of days after receiving&#xD;
      the written information, the potential participant will be contacted and, if the person is&#xD;
      still interested in participating, an information visit will be arranged. If the person&#xD;
      decides to participate, written consent will be obtained. Obtaining of written consent will&#xD;
      be postponed if the potential participant requires more time for consideration. After&#xD;
      obtaining written consent the date for the screening visit is planned.&#xD;
&#xD;
      EXPERIMENTAL DAYS All experiments are carried out at the investigators research facility at&#xD;
      Center for Clinical Metabolic Research at Gentofte Hospital, where all the necessary&#xD;
      equipment and expertise are available. If participants have any ongoing medical treatment,&#xD;
      the participant will be informed to pause the treatment one week prior to each experimental&#xD;
      day. The duration of each experimental day will be approximately 5 hours.&#xD;
&#xD;
      After arriving at the research facility after an overnight (10h) fast (including water,&#xD;
      coffee and medicine), the participant will be asked to empty the urinary bladder and two&#xD;
      urine samples are collected. Two intravenous (iv) catheters will then be inserted in the&#xD;
      cubital veins (one in each arm). One for collection of blood samples and one for&#xD;
      administration of CCK/placebo and GLP-2/placebo. The forearm from which blood samples are&#xD;
      drawn will be wrapped in a heating pad (40-45°C) throughout the experiment for&#xD;
      arterialisation of venous blood. The participant will rest approximately 30 minutes before&#xD;
      start of the experimental procedures. At time 0 min, CCK/placebo infusion will be started. At&#xD;
      time 30 min, the GLP-2/placebo infusion will be started. At time -15, 0, 15, 30, 45, 60, 75,&#xD;
      90, 105, 120, 150, 180, 195, 210 and 240 min, gallbladder height, width and length will be&#xD;
      determined by ultrasonography scans for evaluation of gallbladder volume (calculated by the&#xD;
      ellipsoid method). Blood samples will be collected at time -15, 0, 10, 30, 40, 50, 70, 100,&#xD;
      140, 180, 210 and 240 min. Blood pressure and heart rate will be measured at time -15, 0, 30,&#xD;
      60, 90, 120, 150, 180 and 240 min. The appetite of the participants will be assessed by&#xD;
      Visual Analogue Scale (VAS) at time -15, 0, 15, 45, 75, 105, 135, 180, 210 and 240 min. At&#xD;
      time 180 min the CCK/placebo infusion will be stopped. At time 240 min the GLP-2/placebo&#xD;
      infusion will be stopped. At 240 min, the participants receive a standardized ad libitum meal&#xD;
      consisting of minced meat, pasta, corn, carrots, peppers, cream and salt and pepper.&#xD;
      Participants are instructed to eat as much as they can until they feel comfortably full. The&#xD;
      meal is to be consumed within 30 minutes, and before and after the appetite of the&#xD;
      participants will be evaluated by VAS. After the meal the participant will again be asked to&#xD;
      empty the urinary bladder and two urine samples will be collected.&#xD;
&#xD;
      Data from the study days will be recorded in Clinical Report Forms.&#xD;
&#xD;
      LABORATORY METHODS For bedside measurement of plasma glucose, blood will be sampled into&#xD;
      sodium-fluoride-coated tubes, centrifuged immediately at room temperature and analysed on a&#xD;
      glucose analyzer. For analysis of plasma concentrations of gut-derived hormones degraded by&#xD;
      DPP-4 blood will be collected in chilled tubes (on ice) containing EDTA and the specific&#xD;
      DPP-4 inhibitor valine-pyrrolidide (0.01 ml of 1 mmol/l valine-pyrrolidide solution - 4.3 mg&#xD;
      in 20 ml sterile water/ml blood). For analysis of serum concentrations of other secondary&#xD;
      endpoints blood will be sampled in plain tubes with clot activator for coagulation (10&#xD;
      minutes at room temperature). EDTA and plain tubes will be centrifuged for 15 minutes and&#xD;
      4°C. Plasma/serum samples will be stored at -20°C or -80°C until analysis.&#xD;
&#xD;
      STATISTICS AND CALCULATIONS Data will be processed and presented with the use of standard&#xD;
      descriptive statistics. Area under the curve (AUC) will be calculated by use of the trapezoid&#xD;
      rule. Results will be reported as mean and standard deviation (SD) and as baseline subtracted&#xD;
      AUC (bsAUC). Normally distributed data will be compared using one-way repeated measurements&#xD;
      analysis of variance. Repeated measurement analysis of variance will be used for statistical&#xD;
      analysis of repeated measurements in the same participant. Data that are not normally&#xD;
      distributed will be analyzed using non-parametric tests. P values &lt;0.05 will be considered&#xD;
      statistically significant, i.e. significance level (α) of 5%. Power of the study (1-β) is set&#xD;
      to 80%, where β (20%) is the risk of accepting a hypothesis that is false.&#xD;
&#xD;
      The population size (N) has been calculated using the formula:&#xD;
&#xD;
      N = (Za + Zb)^2 × (SD^2)/(MIREDIF^2), where Za is a table value according to a two-sided&#xD;
      standard normal distribution (1.96), Zb is a table value according to a one-sided standard&#xD;
      normal distribution (0.84). MIREDIF is the minimum relevant difference. SD and MIREDIF are&#xD;
      assessed as bsAUC for gallbladder volume.&#xD;
&#xD;
      The investigators plan to enroll 15 participants. In a previous study with CCK-induced&#xD;
      gallbladder emptying bsAUC (0-120) for gallbladder volume was -1791 ml × min and SD 795.2 ml&#xD;
      × min. Based on these values a 30 % difference in bsAUC for gallbladder volume can be&#xD;
      detected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Day A, B, C and D will be conducted in a randomized and double-blinded order (blinded for the participant and the investigator). The infusion order will be unblinded after the last patient last visit.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Gallbladder volume</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Baseline subtracted area under the curve for gallbladder volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum gallbladder ejection fraction</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 195, 210 and 240 minutes</time_frame>
    <description>Calculated on the basis of gallbladder volume time curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-2</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of GLP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCK</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of CCK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile Acids</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of bile acis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterols</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of cholesterols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Plasma measurement of C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>-15, 0, 10, 30, 40, 50, 70, 100, 140, 180, 210 and 240 minutes</time_frame>
    <description>Measurement of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>-15, 0, 15, 45, 75, 105, 135, 180, 210 and 240 minutes</time_frame>
    <description>Answers to Visual Analog Scales regarding hunger, satiety etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>240-270 minutes</time_frame>
    <description>Meal ingestion (gram)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>-15, 0, 30, 60, 90, 120, 150, 180 and 240 minutes</time_frame>
    <description>Non invasive blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>-15, 0, 30, 60, 90, 120, 150, 180 and 240 minutes</time_frame>
    <description>Non invasive heart rate measurement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Gallbladder</condition>
  <arm_group>
    <arm_group_label>CCK + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCK + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with isotonic NaCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with isotonic NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-2</intervention_name>
    <description>A 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)</description>
    <arm_group_label>CCK + GLP-2</arm_group_label>
    <arm_group_label>Placebo + GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A 210 mins intravenous infusion with isotonic NaCl</description>
    <arm_group_label>CCK + placebo</arm_group_label>
    <arm_group_label>Placebo + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CCK</intervention_name>
    <description>A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1)</description>
    <arm_group_label>CCK + GLP-2</arm_group_label>
    <arm_group_label>CCK + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A 180 mins intravenous infusion with isotonic NaCl</description>
    <arm_group_label>Placebo + GLP-2</arm_group_label>
    <arm_group_label>Placebo + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian ethnicity&#xD;
&#xD;
          -  Male gender&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Body mass index (BMI) 18.5-24.9 kg/m2&#xD;
&#xD;
          -  Fasting plasma glucose ≤6 mmol/l and glycated haemoglobin (HbA1c) ≤ 42 mmol/mol&#xD;
&#xD;
          -  Normal hemoglobin (males 8.3-10.5 mmol/l)&#xD;
&#xD;
          -  Informed and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nephropathy (eGFR &lt; 90 ml/min/1.73m2 and/or albuminuria)&#xD;
&#xD;
          -  Known liver disease and/or alanine aminotransaminase (ALAT) and/or aspartate&#xD;
             transaminase (ASAT) &gt; 2 × upper normal reference limit&#xD;
&#xD;
          -  Active or recent (within 5 years) malignant disease&#xD;
&#xD;
          -  Any history of colon cancer&#xD;
&#xD;
          -  Treatment with medicine that cannot be paused for 1 week&#xD;
&#xD;
          -  Active tobacco smoking&#xD;
&#xD;
          -  Any condition considered incompatible with participation by the investigators&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina L Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Metabolic Research, Genofte University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina L Hansen, MD</last_name>
    <phone>+45 3867 3171</phone>
    <email>nina.lerberg.hansen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip K Knop, MD PhD</last_name>
    <email>filip.krag.knop.01@regionh.dk</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glucagon-Like Peptide 2</keyword>
  <keyword>Gallbladder</keyword>
  <keyword>Gallbladder Motility</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

